Desviat Lourdes R, Pérez Belén, Bèlanger-Quintana Amaya, Castro Margarita, Aguado Cristina, Sánchez Ascensión, García Maria José, Martínez-Pardo Mercedes, Ugarte Magdalena
Centro de Biología Molecular "Severo Ochoa" CSIC-UAM, Madrid, Spain.
Mol Genet Metab. 2004 Sep-Oct;83(1-2):157-62. doi: 10.1016/j.ymgme.2004.06.007.
Tetrahydrobiopterin (BH4) responsiveness in patients with mutations in the phenylalanine hydroxylase (PAH) gene is a recently recognized subtype of hyperphenylalaninemia characterized by a positive BH4 loading test. According to recent estimates, this phenotype may be quite common, suggesting that a large group of individuals may benefit from BH4 substitution, eliminating the need of life-long dietary restrictions. This underscores the importance of identifying BH4-responsive patients in each population, establishing the association with specific PAH mutations. In this work, we describe the results of a pilot study performed with 31 Spanish PAH-deficient patients subjected to a BH4 loading test. Overall, 11/31 (37%) showed a positive response with a 30% decrease in blood Phe levels 8 h after the BH4 challenge, and three additional patients, considered slow responders, showed this decrease only after 12-16 h. We report for the first time a patient homozygous for a splicing mutation with a slow response, suggesting an effect of BH4 supplementation on PAH gene expression. Most of the responsive patients belong to the mild hyperphenylalaninemia (MHP) or mild phenylketonuria phenotypic groups. In MHP patients we report for the first time the results of parallel single Phe doses confirming the utility of these analyses for a better evaluation of the response. Genotype analysis confirms the involvement in the response of specific mutations (D415N, S87R, R176L, E390G, and A309V) present in hemizygous patients, and provide relevant information for the discussion of the potential mechanisms underlying BH4 responsiveness.
苯丙氨酸羟化酶(PAH)基因突变患者的四氢生物蝶呤(BH4)反应性是最近才被认识到的高苯丙氨酸血症的一种亚型,其特征是BH4负荷试验呈阳性。根据最近的估计,这种表型可能相当常见,这表明一大批个体可能从BH4替代中受益,从而无需终身饮食限制。这突出了在每个人群中识别BH4反应性患者的重要性,并建立与特定PAH突变的关联。在这项工作中,我们描述了对31名接受BH4负荷试验的西班牙PAH缺陷患者进行的一项初步研究的结果。总体而言,11/31(37%)表现出阳性反应,在BH4激发后8小时血苯丙氨酸水平下降30%,另外三名被认为是反应缓慢的患者仅在12 - 16小时后才出现这种下降。我们首次报告了一名纯合剪接突变的患者反应缓慢,提示BH4补充对PAH基因表达有影响。大多数反应性患者属于轻度高苯丙氨酸血症(MHP)或轻度苯丙酮尿症表型组。在MHP患者中,我们首次报告了平行单剂量苯丙氨酸分析的结果,证实了这些分析对于更好地评估反应的实用性。基因型分析证实了半合子患者中存在的特定突变(D415N、S87R、R176L、E390G和A309V)与反应有关,并为讨论BH4反应性潜在机制提供了相关信息。